US EditionGreater weight loss promised by higher-dose Wegovy shot, now approved by FDA
Wegovy HD delivers 20.7% average weight loss in trials, enhancing Novo Nordisk's competitive position against Eli Lilly's Zepbound amid rising market challenges.
- The Food and Drug Administration approved Wegovy HD on Thursday, a 7.2 mg higher-dose version of Novo Nordisk's Wegovy injection. FDA Commissioner Dr. Martin Makary noted the approval 'seeks to expedite approval of applications that address critical national health priorities.'
- Novo Nordisk shares fell 28% this year as investors feared the company was losing ground to rival Eli Lilly in the competitive GLP-1 market. The company earlier projected revenue could decline by as much as 13% in 2026, intensifying pressure for new approvals.
- Clinical trials showed Wegovy HD participants lost an average of 20.7% of their body weight, narrowing the gap with Eli Lilly's Zepbound at 22.5% and substantially exceeding the standard Wegovy dose's 15% average weight loss.
- Starting in April, patients can access Wegovy HD at more than 70,000 pharmacies and select telehealth providers. Novo Nordisk recently announced plans to slash prices by up to 50 percent to improve medication affordability.
- Despite trading near its 52-week low with a price-to-earnings ratio just over 10, Novo Nordisk offers a high dividend yielding just over 5%. Wegovy HD approval could signal improved growth prospects for long-term investors despite lingering market skepticism.
8 Articles
8 Articles
New stronger weight-loss drug gets green light from FDA: ‘Major jump’
NEWYou can now listen to Fox News articles! The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long-term weight loss maintenance for adult patients. It is triple the previous maximum dose of 2.4 mg. This marks the fourth approval in the FDA’s National Priority Voucher pilot program, which “seeks to expe…
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer
Key PointsRegulators recently approved Wegovy HD, which is a higher-dose version of its popular weight loss drug.Wegovy HD helped people lose 20.7%, on average, in a clinical trial.The new drug could help Novo Nordisk win back some market share in the GLP-1 market.10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) stock has fallen 28% this year as investors fear that it's falling behind in the competitive GLP-1 market. The com…
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
